Heading in to #ESMO23 ☀️ 😎 to present updated survival results for the phase 2 trial of #neoadjuvant #immunotherapy in resectable cutaneous #squamous #skin #cancer #cSCC cutaneous Squamous Cell Carcinoma (cSCC) Network NEJM AHNS Regeneron MD Anderson Cancer Center

Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic #SkinCancer with high mortality rates. Elina Siljamäki et al. identify PLX8394 as a potential therapeutic compound for advanced and metastatic cSCC. 👉nature.com/articles/s4138…

PD-1-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) ineligible for surgery or radiation. But some patients don’t respond or have severe immune-related adverse events. There is a need for improved therapies. 2/11

Glad to share our collaborative paper with the group of [email protected] on lncRNA PVT1 in cSCC Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity academic.oup.com/bjd/article/do…

My 1st first author preprint is out! Dr. Carolyn Lee, MD/PhD and I analyzed public RNA-Seq data from 147 cutaneous squamous cell carcinoma (cSCC) samples to create a set of robust differentially expressed genes (DEGs) involved in cSCC pathogenesis biorxiv.org/content/10.110… 🧵 below! /1

Expected changes in the Cutaneous Squamous Cell Carcinoma (cSCC) market are driven by improved diagnostics, heightened disease awareness, & upcoming therapy introductions. Learn more about the key factors that profoundly alter the cSCC market dynamics: tinyurl.com/y23v2khw.

PI3K and CDK inhibitors combo against advanced cutaneous squamous cell carcinoma. mdpi.com/2072-6694/16/2…

Extrachromosomal DNA in cutaneous squamous cell carcinoma is associated with increased nodal disease biorxiv.org/content/10.110…

With the advent of RNA-based medicine, PVT1 may be a promising molecular target for the management of inoperable or metastatic cutaneous squamous cell carcinoma (cSCC). Increased expression of PVT1 may serve as a biomarker for cSCCs. doi.org/10.1093/bjd/lj…

Limitations of the Commercially Available Gene Expression Test in Predicting Cutaneous Squamous Cell Carcinoma Metastasis and Clinical Outcomes - Journal of the American Academy of Dermatology jaad.org/article/S0190-…

Leap Hey mate, this is awesome. I am a B.I. Administrator, with a broad experience in IT from dev/coding to testing to DB work. Happy to discuss offline. :-) I am also currently battling stage 4 metastatic cutaneous scc. I am doing what I can where I can to fight it. Or help out

What differentiate $MDNAF from other #IL2 is "Durability" Many are asking me, why $HOWL is down so much despite the CR they had in Cutaneous SCC? So I went back to $HOWL slides & looking deeper into the slide while focusing ONLY on the high dose (disregard all the lower dose

@mranson2 cBioPortal Amarinder Gopal Iyer @jcBeyond5 Ruta Gupta Our first 25 metastatic cSCC WGS 90X/30X. Plenty to explore including clinical data. Thanks again to our generous patients who allowed us access to their tumours.

Very valuable overview and interrogation of data. Great work Lee Lab! Stanford University Stanford Medicine Tomas Bencomo Dr. Carolyn Lee, MD/PhD Gene expression landscape of cutaneous squamous cell carcinoma progression academic.oup.com/bjd/article/do…

⚠️#Hydrochlorothiazide: #cutaneous_squamous_cell_carcinoma (SCC) ☀️In a case-control study, Hydrochlorothiazide users had a 2- to 7-fold increased risk of cutaneous #SCC, with a clear dose-response effect. 😎Patient education on #Sun_avoidance & #Sun_protection is recommended.

An in-depth look at the involvement of kindlin-1 in cutaneous squamous cell carcinoma (SCC). 👀 Drs. Carrasco, Brunton, and colleagues at Edinburgh Cancer Research provide evidence that Kindlin-1 loss 🚫 in SCC can promote invasion through the upregulation of MMP13. 🔗 go.nature.com/3zz41G5

New Post! Thank you to Dr. Michael Baddour, Head & Neck Surgeon at Emory University, who composed this expert review of the importance of understanding perineural spread in cutaneous squamous cell carcinomas of the head and neck. #AHNSSkin AHNS ow.ly/1c9150SzPYB

Most viewed this week from JAMA Oncology: ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk. ja.ma/4eJFcYN

This JAMA Dermatology editorial discusses a novel risk stratification system for cutaneous squamous cell carcinoma that was developed using a retrieval augmented generation–enabled large language model. ja.ma/445Wzzb

Role of CTCF in #cscc progression